INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis

Critical Care Medicine

Volumn 24, Issue 9, 1996, Pages 1431-1440

  Cohen, Jonathan ^a   Carlet, Jean ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b SAINT JOSEPH HOSPITAL   (France)

Author keywords

clinical trial; critical illness; cytokines; interleukin 6; mediators; monoclonal antibody; organ failure; sepsis; septic shock; TNF

Indexed keywords

ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT OUTCOME;

EID: 0029835023     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199609000-00002     Document Type: Article

References (29)

1. Bone RC: Gram-negative sepsis: A dilemma of modern medicine. Clin Microbiol Rev 1993; 6:57-68
2. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328:1471-1477
3. Lynn WA, Cohen J: Adjunctive therapy for septic shock: A review of experimental approaches. Clin Infect Dis 1995; 20:143-158
4. Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i:355-357
5. Girardin E, Grau GE, Dayer J, et al: Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988; 319:397-400
6. Michie HR, Manogue KR, Spriggs DR, et al: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-1486
7. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234:470-474
8. Tracey KJ, Fong Y, Hesse DG, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-664
9. Hinshaw LB, Tekamp-Olson P, Chang AC, et al: Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock 1990; 30:279-292
10. Jesmok G, Lindsey C, Duerr M, et al: Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E. coli-challenged swine. Am J Pathol 1992; 141:1197-1207
11. Fiedler VB, Ingo L, Sander E, et al: Monoclonal antibody to tumor necrosis factor-α prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med 1992; 120:574-588
12. Silva AT, Bayston KF, Cohen J: Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental Gram negative shock. J Infect Dis 1990; 162: 421-427
13. Exley AR, Cohen J, Buurman WA, et al: Monoclonal antibody to TNF in severe septic shock. Lancet 1990; 335:1275-1277
14. Vincent J, Bakker J, Marecaux G, et al: Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study. Chest 1992; 101:810-815
15. Fisher CJ, Opal SM, Dhainaut JF, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21:318-327
16. Saravolatz LD, Wherry JC, Spooner C, et al: Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-α. J Infect Dis 1994; 169:214-217
17. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995; 273:934-941
18. Bone RC, Fisher CJ, Clemmer TP, et al: Sepsis syndrome: A valid clinical entity. Crit Care Med 1989; 17:389-393
19. Emerson TEJ, Lindsey DC, Jesmok G, et al: Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model. Circ Shock 1992; 38:75-84
20. Knaus WA, Draper EA, Wagner DP, et al: APACHE II; a severity of disease classification system. Crit Care Med 1985; 13:818-829
21. McCabe WR, Jackson GG: Gram negative bacteremia. 1. Etiology and ecology. Arch Intern Med 1962; 110:847-855
22. Tran DD, Groenveld AB, Meulen JV, et al: Age, chronic disease, sepsis, organ system failure, and mortality in a medical intensive care unit. Crit Care Med 1990; 18:474-479
23. Aarden LA, de Groot ER, Schaap OL, et al: Production of hybridoma growth factor by human monocytes. Eur J Immunol 1987; 17:1411-1416
24. Ispahani P, Pearson NJ, Greenwood D: An analysis of community and hospital-acquired bacteraemia in a large teaching hospital in the United Kingdom. QJM 1987; 63:427-440
25. Rayner BL, Willcox PA: Community-acquired bacteraemia; a prospective survey of 239 cases. QJM 1988; 69:907-919
26. Freudenberg MA, Galanos C: Tumor necrosis factor alpha mediates lethal activity of killed Gram-negative and Gram-positive bacteria in D-galactosamine-treated mice. Infect Immun 1991; 59:2110-2115
27. Stack AM, Saladino RA, Thompson C, et al: Failure of prophylactic and therapeutic use of a murine anti-tumor necrosis factor monoclonal antibody in Escherichia coli sepsis in the rabbit. Crit Care Med 1995; 23:1512-1518
28. Dhainaut JF, Vincent J, Richard C, et al: CDP571, a humanized antibody to human tumor necrosis factor-α: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. Crit Care Med 1995; 23:1461-1469
29. Bone RC: Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation. Crit Care Med 1996; 24:163-172